Boehringer Ingelheim (Spain)

Recent papers from Boehringer Ingelheim (Spain)

1. Molecular insights into GPR55 modulation reveal an atypical activation mechanism and glycosylation-dependent efficacy regulationNature Communications · 2026
2. A Digital Therapeutic Intervention for Negative Symptoms of SchizophreniaJAMA Network Open · 2026
3. Emergence of a mixed CAF population by FAP-CD3 T-cell engager limits therapeutic efficacyJournal for ImmunoTherapy of Cancer · 2026
4. Structure of Human adenovirus 7 virus-like particles, a platform for developing nanotherapeutics and studying capsid assemblyProceedings of the National Academy of Sciences · 2026
5. SARS-CoV-2 Spike Protein’s Structural Dynamics Affect the Activity of the Bebtelovimab AntibodyJournal of Chemical Information and Modeling · 2026
6. Beamion LUNG-3: Zongertinib in resectable HER2 -mutant NSCLC.Journal of Clinical Oncology · 2026
7. Temporal trends in healthcare resource use and costs of chronic kidney disease in a Spanish population: the REDIC studyThe European Journal of Health Economics · 2026
8. Efficacy and safety of nerandomilast in patients with autoimmune disease-related progressive pulmonary fibrosis in the FIBRONEER-ILD trial.2026
9. Abstract CT080: Open-label, Phase Ib dose-expansion study assessing the efficacy of the CD137/FAP agonist BI 765179 plus pembrolizumab as first-line therapy in metastatic or incurable, recurrent PD-L1-positive head and neck squamous cell carcinomaCancer Research · 2026
10. Nickel/Photoredox-Catalyzed Enantioselective α-Aminoalkylation of 2-IodopyridinesACS Catalysis · 2026
11. Abstract LB-A002: Open-label, Phase Ib dose-expansion study assessing the efficacy of the CD137/FAP agonist BI 765179 plus pembrolizumab as first-line therapy in metastatic or incurable, recurrent PD-L1-positive head and neck squamous cell carcinomaCancer Immunology Research · 2026
12. Abstract LB-A004: DAREON-7: Phase I open-label dose-escalation/-expansion study of first-line obrixtamig (BI 764532) plus chemotherapy in patients with DLL3-positive neuroendocrine carcinomasCancer Immunology Research · 2026
13. Advancing codon language modeling with synonymous codon constrained maskingNucleic Acids Research · 2026
14. Nerandomilast in idiopathic pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-IPF trialAmerican Journal of Respiratory and Critical Care Medicine · 2026
15. A Data-driven Stepwise Approach to Cross Validation of Clinical Anti-Drug Antibody (ADA) AssaysThe AAPS Journal · 2026
16. Optimizing heart failure care transitions: the MAIC Continuum initiative across 25 spanish hospitalsEuropean Heart Journal · 2025
17. Evaluation, Management and Therapeutic Approach of Cardiovascular–Kidney–Metabolic Syndrome: A Multidisciplinary Delphi Expert ConsensusJournal of Clinical Medicine · 2025
18. TCPGdb: A Comprehensive T-cell Perturbation Genomics Database for the Identification of Critical T-cell RegulatorsCancer Immunology Research · 2025
19. Phase Ib study of xentuzumab and abemaciclib in patients with advanced solid tumors and in combination with endocrine therapy in patients with advanced breast cancerESMO Open · 2025
20. The Evaluation of Selected Production Indicators Following the Implementation of Vaccination as Part of a BVDV Eradication Strategy in Two Endemically Infected Beef Suckler HerdsVeterinary Sciences · 2025